The regenerative medicine sector that embraces gene and cell therapies continues to expand, particularly on the business and clinical development fronts. For example, a panel at the Neurosciences 2018 conference discussed just how rapidly the science is evolving and now beginning to take on harder-to-treat diseases, with gene therapies already in early stage development targeting amyotrophic lateral sclerosis, Parkinson's disease and Batten disease.